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A B S T R A C T
Background
Catamenial epilepsy describes a worsening of seizures in relation to the menstrual cycle and may affect around 40% of women with epilep-
sy. Vulnerable days of the menstrual cycle for seizures are perimenstrually (C1 pattern), at ovulation (C2 pattern), and during the luteal
phase (C3 pattern). A reduction in progesterone levels premenstrually and reduced secretion during the luteal phase is implicated in cata-
menial C1 and C3 patterns. A reduction in progesterone has been demonstrated to reduce sensitivity to the inhibitory neurotransmitter in
preclinical studies, hence increasing risk of seizures. A pre-ovulatory surge in oestrogen has been implicated in the C2 pattern of seizure
exacerbation, although the exact mechanism by which this surge increases risk is uncertain. Current treatment practices include the use
of pulsed hormonal (e.g. progesterone) and non-hormonal treatments (e.g. clobazam or acetazolamide) in women with regular menses,
and complete cessation of menstruation using synthetic hormones (e.g. medroxyprogesterone (Depo-Provera) or gonadotropin-releasing
hormone (GnRH) analogues (triptorelin and goserelin)) in women with irregular menses.
Catamenial epilepsy and seizure exacerbation is common in women with epilepsy, and may have a significant negative impact on quality
of life. Women may not be receiving appropriate treatment for their seizures because of uncertainty regarding which treatment works best
and when in the menstrual cycle treatment should be taken, as well as the possible impact on fertility, the menstrual cycle, bone health,
and cardiovascular health. This review aimed to address these issues in order to inform clinical practice and future research.
Objectives
To evaluate the efficacy and tolerability of hormonal and non-hormonal treatments for seizures exacerbated by the menstrual cycle in
women with regular or irregular menses. We synthesised the evidence from randomised controlled trials of hormonal and non-hormonal
treatments in women with catamenial epilepsy of any pattern.
Search methods
We searched the following databases to 10 January 2019: Cochrane Register of Studies (CRS Web; includes the Cochrane Epilepsy Group
Specialized Register and the Cochrane Central Register of Controlled Trials (CENTRAL)), MEDLINE (Ovid: 1946 to 9 January 2019), Clinical-
Trials.gov, and the World Health Organization (WHO) International Clinical Trials Registry Platform (ICTRP). We used no language restric-
tions. We checked the reference lists of retrieved studies for additional reports of relevant studies.
Selection criteria
We included randomised and quasi-randomised controlled trials (RCTs) of blinded or opeṉlabel design that randomised participants in-
dividually (i.e. cluster-randomised trials were excluded). We included cross-over trials if each treatment period was at least 12 weeks in
length and the trial had a suitable wash-out period. Types of interventions included: women with any pattern of catamenial epilepsy who
received a hormonal or non-hormonal drug intervention in addition to an existing antiepileptic drug regimen for a minimum treatment
duration of 12 weeks.
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Data collection and analysis
We extracted data on study design factors and participant demographics for the included studies. The primary outcomes of interest were:
proportion seizure-free, proportion of responders (at least 50% decrease in seizure frequency from baseline), and mean change in seizure
frequency. Secondary outcomes included: number of withdrawals, number of women experiencing adverse events of interest (seizure ex-
acerbation, cardiac events, thromboembolic events, osteoporosis and bone health, mood disorders, sedation, menstrual cycle disorders,
and fertility issues), and quality of life outcomes.
Main results
We identified 62 records from the databases and search strategies. Following title, abstract, and full-text screening, we included eight full-
text articles reporting on four double-blind, placebo-controlled RCTs. We included two cross-over RCTs of pulsed norethisterone and two
parallel RCTs of pulsed progesterone recruiting a total of 192 women aged between 13 and 45 years with catamenial epilepsy. We found
no RCTs for non-hormonal treatments of catamenial epilepsy or for women with irregular menses.
Meta-analysis was not possible for the primary outcomes, therefore we undertook a narrative synthesis. For the two RCTs evaluating
norethisterone versus placebo (24 participants), there were no reported treatment differences for mean change in seizure frequency. Out-
comes for the proportion seizure-free and 50% responders were not reported. For the RCTs evaluating progesterone versus placebo (168
participants), the studies reported conflicting results on the primary outcomes. One progesterone RCT reported no significant difference
between progesterone 600 mg/day taken on day 14 to 28 and placebo with respect to 50% responders, seizure freedom rates, and change
in seizure frequency for any seizure type. The other progesterone RCT reported that the decrease in seizure frequency from baseline in the
progesterone group was significantly higher than the decrease in seizure frequency from baseline in the placebo group.
Results of secondary efficacy outcomes showed no significant difference in terms of treatment withdrawal for any reason in the pooled
progesterone RCTs when compared to placebo (pooled risk ratio (RR) 1.56, 95% confidence interval (CI) 0.81 to 3.00, P = 0.18, I2 = 0%)
or for treatment withdrawals due to adverse events (pooled RR 2.91, 95% CI 0.53 to 16.17, P = 0.22, I2 = 0%). No treatment withdrawals
from the norethisterone RCTs were reported. The RCTs reported limited information on adverse events, although one progesterone RCT
reported no significant difference in the number of women experiencing adverse events (diarrhoea, dyspepsia, nausea, vomiting, fatigue,
nasopharyngitis, dizziness, headache, and depression). No studies reported on quality of life.
We judged the evidence from the included progesterone RCTs to be of low to moderate certainty due to risk of bias and from the included
norethisterone RCTs to be of very low certainty due to serious imprecision and risk of bias.
Authors' conclusions
This review provides very low-certainty evidence of no treatment difference between norethisterone and placebo, and moderate- to low-
certainty evidence of no treatment difference between progesterone and placebo for catamenial epilepsy. However, as all the included
studies were underpowered, important clinical effects cannot be ruled out.
Our review highlighted an overall deficiency in the literature base on the effectiveness of a wide range of other hormonal and non-hormonal
interventions currently being used in practice, particularly for those patients who do not have regular menses. Further clinical trials are
needed in this area.
P L A I N   L A N G U A G E   S U M M A R Y
Treatments for seizures in catamenial (menstrual-related) epilepsy
Background
Catamenial (menstrual) epilepsy describes a worsening of seizures in relation to the menstrual cycle and may affect around 40% of women
with epilepsy. There are specific times within the menstrual cycle when women are most at risk: in the days leading up to a menstrual period
and during a menstrual period (perimenstrual or catamenial type 1 pattern); at the time of ovulation (catamenial type 2 pattern); and in the
second half of their cycle (luteal phase or catamenial type 3 pattern). The reason for this increased risk may relate to changes in the levels
of progesterone around the time of a menstrual period and oestrogen surge around ovulation. Studies in animals have demonstrated
that lower progesterone may affect how the brain reacts to the brain chemical gamma-Aminobutyric acid (GABA), which is important in
preventing seizures. The link between high levels of oestrogen and risk of seizures remains unclear.
At present, catamenial epilepsy is treated depending on whether a woman has regular or irregular menstrual periods. If a woman has
regular periods, hormonal (e.g. progesterone supplements) and non-hormonal treatments (e.g. clobazam or acetazolamide) taken prior
to and during a period may be used. In women who do not have regular periods, and therefore cannot predict their period days, stop-
ping periods using synthetic hormones (e.g. medroxyprogesterone (Depo-Provera) or gonadotropin-releasing hormone (GnRH) analogues
(triptorelin and goserelin)) are treatment options.
Catamenial epilepsy is common in women with epilepsy, and may have a significant negative impact on quality of life. Women may not
be receiving appropriate treatment for their catamenial seizures. There is uncertainty regarding which treatment works best and when in
Treatments for seizures in catamenial (menstrual-related) epilepsy (Review)
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the menstrual cycle treatments should be taken. There are also concerns about the possible impact on fertility, the menstrual cycle, bone
health, and cardiovascular health. This review aimed to address these issues in order to inform clinical practice and future research.
Objectives
The aim of the review was to examine the effectiveness of hormonal and non-hormonal treatments in stopping seizures in women with
catamenial epilepsy.
Methods
Our latest search for trials was in January 2019. We searched the electronic databases to find relevant randomised and quasi-randomised
controlled trials (RCTs) (studies in which participants are assigned to one of two or more treatment groups using a random method) in
which treatment was continued for at least 12 weeks. Our outcomes of interest were: average change in seizures, percentage of women
achieving a reduction in seizures by at least 50%, and percentage of women who became seizure-free. We also examined the reasons why
women dropped out of the studies and the reported side effects.
Results
Out of 62 records found in our searches, we were able to include four RCTs of hormonal treatments: two trials evaluating progesterone, and
two evaluating norethisterone. In all of these RCTs, the treatment was compared to a placebo (a harmless sugar pill). We did not find any
studies testing non-hormonal treatments or any studies in women with irregular periods. The four RCTs included 192 participants aged
between 13 and 45 years experiencing catamenial epilepsy. The RCTs did not demonstrate any significant differences when comparing
progesterone or norethisterone to placebo for seizure outcomes. The RCTs reported limited information on side effects, but women taking
progesterone were no more likely to withdraw from the study due to side effects than those on placebo.
Certainty of the evidence
We judged the certainty of the evidence from this review to be very low to moderate, as the RCTs provided unclear information on methods
of blinding, recruited small numbers of participants, and were inconsistent in reporting treatment outcomes.
Conclusions
We found very limited, mostly low-certainty evidence, of no difference in seizure outcomes for norethisterone and progesterone versus
placebo in women with catamenial epilepsy. Our review highlights an overall lack of information on the effectiveness of a wide range of
other hormonal and non-hormonal treatments currently being used. Further clinical studies are needed in this area.
Treatments for seizures in catamenial (menstrual-related) epilepsy (Review)














































































S U M M A R Y   O F   F I N D I N G S
 
Summary of findings for the main comparison.   Norethisterone compared to placebo for perimenstrual seizures in catamenial epilepsy
Norethisterone compared to placebo for perimenstrual seizures in catamenial epilepsy




Illustrative comparative risks* (95% CI)















Outcome not reported NA  
Responder rate
Follow-up: NA
Outcome not reported NA  
Change in seizure frequen-
cy
Follow-up: up to 14 months
Neither of the studies showed any significant differences between


































































































































































Follow-up: up to 14 months
Adverse events
Follow-up: up to 14 months
4 "mild" types of adverse event that were considered to be relat-
ed to the trial medication were reported: irregularities in menstru-
al cycle (5 women), facial rash (1 woman), headaches (2 women),





















Outcome not reported NA  
*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is
based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: confidence interval; NA: not applicable
GRADE Working Group grades of evidence
High certainty: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate certainty: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low certainty: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low certainty: We are very uncertain about the estimate.
1Downgraded three times due to serious imprecision and risk of bias: the two included studies used a cross-over design, had a very small sample size, and reported limited
information regarding study design and numerical results.
 
 
Summary of findings 2.   Progesterone compared to placebo for perimenstrual seizures in catamenial epilepsy
Progesterone compared to placebo for perimenstrual seizures in catamenial epilepsy











































































































































Illustrative comparative risks* (95% CI)





















4% of women in the proges-
terone group achieved free-







There was also no significant difference
between treatments in terms of freedom
from the most severe seizure type (RR







200 per 1000 228 per 1000







There was also no significant difference
between treatment in terms of respon-
der rate for the most severe seizure type
(RR 1.24, 95% CI 0.67 to 2.29) or when
considering each seizure type individ-







1 study (n = 36) reported that the decrease in seizure
frequency from baseline in the progesterone group
was significantly higher than the decrease in seizure
frequency from baseline in the placebo group (P =
0.024).
1 study (n = 130) reported no significant differences
between treatments with respect to proportional
changes for all seizures combined, most severe seizure
type, or each seizure type considered separately






Due to different methods of data pre-








141 per 1000 219 per 1000







There was also no significant difference
between progesterone and placebo in
terms of
treatment withdrawals due to adverse





511 per 1000 434 per 1000







There was no significant difference be-
tween progesterone and placebo in the
proportion of women experiencing spe-
cific adverse events occurring in at least










































































































































sia, nausea, vomiting, nasopharyngitis,
fatigue, dizziness, headache, and de-
pression)
In the other study (n = 36), 2 women
were excluded from the study due
to progesterone side effects (severe
headache, nausea and vomiting). No fur-
ther information on adverse events was
provided in this study.
Quality of life
Follow-up: NA
Outcome not reported NA  
*The basis for the assumed risk is the event rate in the placebo group. The corresponding risk (and its 95% confidence interval) is based on the assumed risk in the com-
parison group and the relative effect of the intervention (and its 95% CI).
CI: confidence interval; NA: not applicable; RR: risk ratio
GRADE Working Group grades of evidence
High certainty: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate certainty: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low certainty: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low certainty: We are very uncertain about the estimate.
1Downgraded once due to risk of bias: unclear methodological information regarding allocation concealment and attrition in the included trial(s). One of the trials was terminated
early due to futility analyses and is therefore statistically underpowered.
2Downgraded once due to imprecision: confidence intervals around the treatment effect are very wide due to the small number of events.
3Downgraded once due to inconsistency: results of the two studies could not be combined in meta-analysis due to different methods of presenting the outcome. Study-specific
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B A C K G R O U N D
Description of the condition
Studies have shown that in developed countries, prevalence rates
for active epilepsy are between 4 and 10 per 1000 (Sander 1996).
In a systematic review of incidence studies, the median annual in-
cidence of epilepsy was 50.7 per 100,000 for males and 46.2 per
100,000 for females (Kotsopoulos 2002). Globally, 50% of women
and girls with epilepsy are in the reproductive age range of 15 to 49
years.
Catamenial epilepsy describes a worsening of seizures in relation
to the menstrual cycle, which may affect around 40% of women
with epilepsy (Herzog 1997). Studies examining day-to-day com-
parisons of seizures throughout the menstrual cycle have consis-
tently shown a greater likelihood of seizures on day one (the start
of menstruation), with the lowest risk of seizures on day 20 (the
mid-luteal phase) (Laidlaw 1956; Rosciszewska 1980; Ansell 1986;
Tauboll 1991; Herzog 1997). The menstrual cycle is characterised by
two phases: the follicular phase (day one to day 13), which compris-
es menstruation (day one to five) followed by ovulation (day 14),
and the luteal phase (day 15 to 28). There are two major hormon-
al changes: a preovulatory surge in oestradiol (day 10 to 15), and
a premenstrual drop in progesterone levels (day 25 to 28). In one
study of 184 women with focal epilepsy, there was statistically sig-
nificant evidence for greater seizure occurrences around the time
of these two critical hormonal changes, compared with the mid-fol-
licular and mid-luteal phases. These time periods were categorised
as catamenial type 1 (C1) pattern (day −3 (25) to day 3) and cata-
menial type 2 (C2) pattern (day 10 to 15). A third pattern - catame-
nial type 3 (C3) - was noted in patients experiencing anovulatory
cycles (where no ovulation occurs during the cycle), whereby a lack
of progesterone secretion during the luteal phase predisposed to a
higher mid-luteal ratio of oestradiol to progesterone, which placed
the patient at risk of seizures throughout the luteal phase (Herzog
1997). The hormonal changes and catamenial seizure patterns dur-
ing a menstrual cycle are summarised in Figure 1.
 
Figure 1.   Figure 1: Hormonal changes and catamenial seizures patterns during the menstrual cycle Reprinted
from Reddy DS. Neurosteroids and their role in sex-specific epilepsies. Neurobiology of Disease72 (pt B):198-209,
Copyright (2014), with permission from Elsevier (Reddy 2014)
 
Approximately 10% of menstrual cycles in healthy women are
anovulatory, whereas 35% are anovulatory in women with tem-
poral lobe epilepsy (Herzog 2001). In a study conducted in 1997,
around 42% of women with epilepsy demonstrated at least one of
the three patterns of catamenial epilepsy. Around 36% had C1 pat-
tern, 29% had C2 pattern, and 42% had C3 pattern (Herzog 1997).
Other studies have reported higher prevalence rates (between 63%
and 78%), however they compared seizures in just perimenstrual
phases versus other phases of the cycle (Laidlaw 1956; Rosciszews-
ka 1980; Ansell 1986; Tauboll 1991). When a similar comparison was
Treatments for seizures in catamenial (menstrual-related) epilepsy (Review)
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made in the 1997 study, a prevalence rate of 71% was found (Her-
zog 1997). Reported clinical risk factors for catamenial epilepsy are:
younger age, temporal lobe seizures, and a leR-sided epileptogenic
foci, which implies that cyclical seizure rhythms are affected by the
neuroanatomic substrate of the seizure focus (Quigg 2009).
Description of the intervention
In individuals with catamenial seizures, non-hormonal and hor-
monal treatments may be considered in addition to regular
medication. Non-hormonal treatments include pulsed clobazam
and acetazolamide. Hormonal treatments include natural prog-
esterone supplements, synthetic oral or intramuscular proges-
terones, allopregnanolone, and gonadotropin-releasing hormone
(GnRH) analogues (triptorelin and goserelin).
For women with catamenial epilepsy who have regular menstrual
cycles, intermittent treatment approaches are considered. These
interventions target vulnerable days of the menstrual cycle peri-
menstrually (C1 pattern), at ovulation (C2 pattern), and during the
luteal phase (C3 pattern). The National Institutes of Health prog-
esterone trial assigned 462 women with drug-resistant seizures to
either oral progesterone or placebo taken during days 14 to 28
(Herzog 2012), and observed changes in seizure frequency (a re-
duction of more than 50%) between the three-month baseline and
the three-month treatment period. The study found comparable
outcomes for progesterone and placebo overall. However, a sec-
ondary analysis identified that the women most likely to respond
were those with a C1 pattern seizure type (secondary generalised
seizures and focal seizures with altered awareness) and a threefold
higher perimenstrual seizure frequency. The study demonstrated
a favourable short-term safety profile (Herzog 2012). However, the
study did not show a clear effect in women with C2 or C3 pattern,
which may reflect differences in underlying pathophysiology. Oth-
er intermittent cyclic treatments include benzodiazepines, aceta-
zolamide, or increasing the dose of an antiseizure drug already in
use.
For women with irregular menstrual cycles, or in those for whom
the intermittent cyclic treatments are not effective, the option of
pharmacologically stopping the menstrual cycle altogether may be
considered, either by using synthetic hormones such as medrox-
yprogesterone (Depo-Provera), GnRH analogues (triptorelin and
goserelin), or sustained oral contraceptives.
How the intervention might work
Preclinical studies have demonstrated that withdrawal of prog-
esterone or its reduced metabolite allopregnanolone, as occurs
premenstrually, can cause insensitivity to the inhibitory neuro-
transmitter gamma-Aminobutyric acid (GABA) and also to benzodi-
azepines that act to enhance GABA transmission (Gangisetty 2010).
This is thought to occur by the alteration in the subunit compo-
sition of the GABA-A receptor (Maguire 2005). In animal models,
progesterone has been found to reduce neuronal firing and de-
crease spontaneous and induced epileptiform discharges (Red-
dy 2004). Progesterone has demonstrated effects on reducing the
number of excitatory synapses and the number of oestrogen re-
ceptors (McEwen 2001). Other experimental studies support the
role of allopregnanolone (a metabolite of progesterone) as confer-
ring seizure protection, with the role of progesterone largely unex-
plained (Kokate 1999).
The mechanism by which oestradiol causes seizures is uncertain
(Osborne 2009). It may regulate the limbic system; there is evi-
dence of oestradiol synthesising enzymes present within the hip-
pocampus of the temporal lobe. It has also been hypothesised that
oestradiol increases excitation by enhancing glutamate transmis-
sion and associated receptors (Woolley 1994; Smejkalova 2010).
Several studies of chronic oestrogen administration in females,
however, show either anticonvulsant effects or no effect of oestro-
gen on seizures. Studies have also demonstrated that, in low dos-
es, oestradiol can produce neuroprotective effects (Velísková 2000;
Kalkbrenner 2003). Modulation of enzymes involved in glutamate
breakdown to GABA have been proposed as neuroprotective mech-
anisms (Joh 2006; Ledoux 2009).
A detailed understanding of the patterns and pathophysiology is
paramount for the development of rational approaches for pre-
venting and treating catamenial epilepsy.
Why it is important to do this review
Catamenial epilepsy and seizure exacerbation is common in
women with epilepsy, and may have a significant negative impact
on quality of life. Women may not be receiving appropriate treat-
ment for their catamenial seizures because of uncertainty regard-
ing which treatment works best and when in the menstrual cycle
treatment should be taken, as well as the possible impact on fer-
tility, the menstrual cycle, bone health, and cardiovascular health.
This review aimed to address these issues to inform clinical prac-
tice and future research.
O B J E C T I V E S
To evaluate the efficacy and tolerability of hormonal and non-hor-
monal treatments for seizures exacerbated by the menstrual cycle
in women with regular or irregular menses. We synthesised the ev-
idence from randomised and quasi-randomised controlled trials of
hormonal and non-hormonal treatments in women with catame-
nial epilepsy of any pattern.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We included randomised and quasi-randomised controlled trials
of blinded or open-label design. We only included studies that
randomised participants individually (i.e. cluster-randomised trials
were not included). We included trials with a cross-over design if
each treatment period was at least 12 weeks in length and the trial
had a suitable wash-out period.
Types of participants
We included women of childbearing age who had experienced a
catamenial pattern of seizures in at least two baseline cycles, de-
fined as one or more of the following.
1. C1 pattern: a greater average daily seizure frequency during the
perimenstrual phase (days −3 to +3) compared with the mid-fol-
licular phase (days 4 to 9) and mid-luteal phase (days −12 to 14)
in normal ovulatory cycles.
2. C2 pattern: a greater average daily seizure frequency during the
periovulatory phase (days 10 to −13) compared to the mid-fol-
Treatments for seizures in catamenial (menstrual-related) epilepsy (Review)
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licular phase (days 4 to 9) and mid-luteal phase (days −12 to 14)
in normal ovulatory cycles.
3. C3 pattern: a greater average daily seizure frequency during the
luteal phase (days 15 to 28) compared to the follicular phase
(days 1 to 14) in anovulatory cycles.
Types of interventions
We included the following intervention and control groups.
• Intervention group: women who received a hormonal or
non-hormonal drug intervention in addition to an existing
antiepileptic drug regimen for a minimum treatment duration of
12 weeks.
• Control group(s): women who received a placebo, comparative
drug intervention, or no treatment in addition to an existing
antiepileptic drug regimen for a minimum treatment duration of
12 weeks.
Types of outcome measures
Primary outcomes
1. Seizure freedom, defined as the proportion of women who be-
came seizure-free over the treatment period.
2. Responder rate, defined as the proportion of women with a 50%
reduction in seizure frequency compared to baseline.
3. Change in seizure frequency, defined as the absolute and per-
centage change in seizure frequency compared to baseline.
Secondary outcomes
1. Withdrawals, defined as the number of withdrawals from allo-
cated treatment or from the trial.
a. Withdrawals for any reason
b. Withdrawals due to lack of efficacy
c. Withdrawals due to adverse events
2. Adverse events: of interest (outlined below), including serious
adverse events, and other events reported in the trials regard-




d. Osteoporosis and bone health
e. Mood disorders
f. Sedation
g. Menstrual cycle disorders
h. Fertility issues
3. Quality of life, according to validated general scales such as the
36-Item Short Form Health Survey (SF-36), EuroQol 5-Dimen-
sions (EQ-5D), or epilepsy-specific scales such as the Quality Of
Life In Epilepsy-31 (QOLIE-31).
a. Total quality of life score
b. Domain-specific scores of quality of life scales
Quality of life was not reported by any of the studies included in the
current version of the review. If quality of life is reported in future
versions of this review, in the first instance, we will report change
from baseline in quality of life, and if change-from-baseline scores
are not available, we will report the final scores.
Search methods for identification of studies
Electronic searches
We searched the following databases on 10 January 2019, with no
language restrictions. We sought translation of reports published
in any languages other than English.
1. Cochrane Register of Studies (CRS Web; includes the Cochrane
Epilepsy Group Specialized Register and the Cochrane Central
Register of Controlled Trials (CENTRAL)), using the search strat-
egy shown in Appendix 1.
2. MEDLINE (Ovid) 1946 to 9 January 2019, using the search strate-
gy shown in Appendix 2.
3. US National Institutes of Health Ongoing Trials Register Clinical-
Trials.gov (clinicaltrials.gov/), using the search strategy shown
in Appendix 3.
4. World Health Organization International Clinical Trials Registry
Platform (WHO ICTRP) (apps.who.int/trialsearch/), using the
search strategy shown in Appendix 4.
Searching other resources
We reviewed the reference lists of retrieved trials to check for addi-
tional reports of relevant studies.
Data collection and analysis
Selection of studies
The two review authors (MM and SJN) independently assessed
trials for inclusion using the Cochrane Covidence software (Covi-
dence). We first screened the titles and abstracts of the records, ex-
cluding any that were clearly irrelevant. We then screened the full-
text articles for inclusion, recording the excluded studies and the
reasons for their exclusion. Any disagreements between the review
authors regarding eligibility of trials were resolved by discussion.
The screening process is displayed in a PRISMA study flow diagram
(Figure 2) (Moher 2009).
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Figure 2.   Study flow diagram.
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Data extraction and management
We extracted the following information for each trial using a data
extraction form.
Methodology/trial design
1. Method of randomisation and concealment
2. Method of blinding
3. Trial inclusion and exclusion criteria
4. Number of people excluded from analyses
5. Duration of trial periods, e.g. baseline, treatment, and follow-up
periods, and total trial duration
6. Trial intervention treatment: type of drug and dose
7. Trial control treatment: type of control (including type of drug
and dose if applicable)
8. Source of funding of the trial and author disclosures
Participant demographics
1. Total number of women randomised to each group
2. Age (overall and by treatment group)
3. Epilepsy/seizure type
4. Epilepsy duration and aetiology
5. Existing antiepileptic drug regimen (including dose, overall and
by treatment group)
6. Baseline seizure frequency (overall and by treatment group)
7. Proportion with C1, C2, and C3 catamenial pattern of seizures
Results
1. Number of women included in analysis of each outcome by
treatment group
2. Outcome summary data for each intervention (see Types of out-
come measures)
The two review authors (MM and SJN) independently extracted da-
ta for each trial and compared extractions. We piloted the content
of the form on an eligible trial and added to the content if required.
Any discrepancies in data extracted by the two review authors were
resolved by discussion.
If any of the above information was recorded but not published
within the trial reports, or if information was unclear, we contacted
the original trial authors for clarification.
Assessment of risk of bias in included studies
The two review authors (MM and SJN) independently assessed the
risk of bias for each trial using the Cochrane 'Risk of bias' tool, as
described in the Cochrane Handbook for Systematic Reviews of In-
terventions (Higgins 2011a). We rated each of the following six do-
mains as low, high, or unclear risk of bias: method of generating
random sequence, allocation concealment, blinding methods, in-
complete outcome data, selective outcome reporting, and other
sources of bias.
For included cross-over studies, we also considered additional cri-
teria for assessing risk of bias in cross-over studies described in Sec-
tion 16.4.3 in the Cochrane Handbook for Systematic Reviews of In-
terventions (Higgins 2011b), and summarised any specific concerns
relating to the cross-over design for the domain other sources of
bias.
Any discrepancies in the 'Risk of bias' judgements between the two
review authors were resolved by discussion.
Measures of treatment e<ect
We reported dichotomous data (seizure freedom, responder rate,
withdrawals, and adverse events) as risk ratios (RRs) with 95% con-
fidence intervals (CIs). Where a large number of different adverse
events were reported across the studies (e.g. more than five differ-
ent adverse events), we reported 99% CIs for this outcome to ac-
count for multiplicity of statistical testing.
We reported change in seizure frequency as the mean difference
(MD) in the change from baseline, with 95% CIs.
None of the studies included in the current version of this review
reported on quality of life. If quality of life is reported in future ver-
sions of the review, we will report it as MD with 95% CIs where the
same scales are used across studies. If different quality of life scales
are reported across studies, we will consider the similarity of the
domains and questions of the scales, and if we deem the different
scales to be sufficiently similar, we will report pooled quality of life
scores as the standardised mean difference (SMD) with 95% CIs. If
the different scales are deemed insufficiently similar to combine,
we will report each scale in separate analyses (where data allow),
or in a narrative review.
Unit of analysis issues
We only included studies that randomised participants individual-
ly (i.e. cluster-randomised trials were not included). We included
cross-over trials if each treatment period was a least 12 weeks in
length and the trial had a suitable wash-out period.
For cross-over studies, in the first instance, we intended to use
methods recommended by Elbourne for pooling cross-over data,
which take account of the correlation between measurements tak-
en from the same group of participants via paired analyses (El-
bourne 2002). Alternatively, if suitable data were not available, we
may have been able to either use the first-period data only, or to
treat the cross-over studies as if they were parallel studies, which is
a conservative approach and does not take account of within-par-
ticipant correlation. However, the two included cross-over trials re-
ported very limited information about the study design and numer-
ical results, therefore we reported the results of these cross-over
studies narratively (Dana-Haeri 1983; Cleland 1995).
Had we identified trials with more than two treatment arms (e.g.
drug A, drug B, and placebo), we intended to construct separate
head-to-head comparisons to consider the different pairs of inter-
ventions and controls.
Dealing with missing data
We recorded the attrition rates reported in each trial and, if possible
and appropriate, contacted the original trial authors if the extent of
missing data was unclear. In order to permit an intention-to-treat
analysis within this review, we extracted and reported data by ran-
domised treatment groups where possible, irrespective of compli-
ance with allocated treatment, exclusion from analysis, or loss to
follow-up.
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In the event of substantial amounts of missing outcome data,
we considered the potential bias that may have been introduced
when interpreting the results, particularly if the missing data were
deemed to not be missing at random.
If appropriate, for the primary outcomes of seizure freedom and re-
sponder rate, we planned to consider sensitivity analyses such as
best-case scenario and worst-case scenario analyses (in the best-
case scenario, individuals in the treatment group are assumed to
have a good outcome and those in the control group are assumed
to have a bad outcome; in the worst-case scenario the opposite is
assumed).
Assessment of heterogeneity
We assessed clinical heterogeneity by reviewing the differences
across trials in design, characteristics of recruited participants, and
interventions. Where meta-analysis could be conducted, we also
estimated heterogeneity statistically using a Chi2 test for hetero-
geneity (with a conservative judgement of P value less than 0.1 sug-
gesting heterogeneity), and the I2 statistic. We interpreted the I2
statistic as follows (Deeks 2011):
1. 0% to 40% might not be important;
2. 30% to 60% may represent moderate heterogeneity;
3. 50% to 90% may represent substantial heterogeneity;
4. 75% to 100%: considerable heterogeneity.
Assessment of reporting biases
If a sufficient number of trials (10 or more) were included in any
comparison, we intended to investigate publication bias by using a
funnel plot and examining any asymmetry. However, fewer than 10
studies were included for the two comparisons of the review, there-
fore we could not examine funnel plots.
To assess selective reporting bias, we compared the measurements
and outcomes planned by the original investigators during the tri-
al with those reported within the published paper by checking the
trial protocols (when available) against the information in the fi-
nal publication. Where published protocols were not available and
the trial authors did not provide an unpublished protocol upon re-
quest, we compared the methods and the results sections of the
published papers. We also used our knowledge of the clinical area
to identify where trial investigators had not reported commonly
used outcome measures.
Data synthesis
We planned that where trials were deemed sufficiently homoge-
nous in design, participant characteristics, and interventions, we
would perform meta-analysis using Mantel-Haenszel methodology
for dichotomous data and inverse-variance methodology for con-
tinuous data (see Measures of treatment effect). We intended to use
a fixed-effect meta-analysis model in the first instance. If we found
substantial or considerable heterogeneity (i.e. an I2 value of more
than 50%), we would repeat the meta-analysis with a random-ef-
fects model and compare the results of both models.
Where we deemed that the designs, participant characteristics, and
interventions were too heterogeneous to combine data, we would
report the results in a narrative review. Where appropriate, we in-
tended to present outcome data in tables or enter trial-specific da-
ta into forest plots for visual purposes, without pooling any out-
come data.
For most of the outcomes of the two comparisons in this review,
trial-specific data only were entered into forest plots or results were
reported narratively.
Subgroup analysis and investigation of heterogeneity
We assessed clinical and statistical heterogeneity using the meth-
ods outlined in Assessment of heterogeneity.
If appropriate, and if data allowed, we planned to conduct the fol-
lowing subgroup analyses for all outcomes.
1. Type of epilepsy (focal versus generalised onset, and temporal
versus extratemporal onset)
2. Type of seizure (e.g. focal seizure without altered awareness,
focal seizure with altered awareness, secondary generalised
seizure, primary generalised seizure, myoclonic seizure, ab-
sence seizure).
3. Catamenial pattern (C1, C2, and C3)
4. Age groups, as defined by the trials (e.g. puberty, sexual maturi-
ty, perimenopausal)
The data reported in the included studies did not permit subgroup
analyses of type of epilepsy, catamenial pattern, or age groups. One
trial reported seizure outcome results by type of seizure; we have
presented these results in Effects of interventions (Herzog 2012).
Sensitivity analysis
As outlined in Dealing with missing data, if substantial outcome da-
ta were missing and where appropriate, we would consider sensi-
tivity analyses such as best-case scenario and worst-case scenario
analyses.
Where appropriate, we would also consider performing a sensitiv-
ity analysis excluding studies at high risk of bias across any of the
domains outlined in Assessment of risk of bias in included studies.
'Summary of findings' and certainty of the evidence
We generated a 'Summary of findings' table for each comparison
in the review (Summary of findings for the main comparison; Sum-
mary of findings 2), including all outcomes (Schünemann 2011):
seizure freedom, responder rate, change in seizure frequency, with-
drawals, adverse events, and quality of life.
For clarity and brevity in the tables, we reported a general state-
ment about the summary of findings for secondary outcomes (with-
drawals, adverse events, quality of life), based on different reasons
for withdrawal, different adverse events, and different quality of life
scales.
We determined the certainty of the evidence using the GRADE ap-
proach (Atkins 2004), and downgraded the evidence in the pres-
ence of a high risk of bias in at least one study, due to incomplete-
ness of the evidence, unexplained heterogeneity or inconsistency,
imprecision of results, and high probability of publication bias. We
downgraded the evidence by one level if we considered the limita-
tion to be serious, and by two levels if very serious.
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Description of studies
See: Characteristics of included studies; Characteristics of exclud-
ed studies
Results of the search
The searches outlined above (see Electronic searches) identified 61
records. We found one additional record from other sources. Fol-
lowing removal of 20 duplicates, we screened 42 records and ex-
cluded 24 based on title and abstract. We further screened the re-
maining 18 records, accessing full texts where available. We includ-
ed four studies reported in eight records, excluded four studies re-
ported in seven records, and assessed two studies reported in three
records as awaiting classification due to insufficient published in-
formation to currently include these studies in the review (see Char-
acteristics of studies awaiting classification).
A PRISMA study flow diagram is shown in Figure 2.
Included studies
We found four randomised, placebo-controlled, double-blind stud-
ies of progesterone therapy used for seizures in catamenial epilep-
sy that reported on the primary efficacy outcome and that met our
inclusion criteria. Two of these trials were parallel-group studies
(Herzog 2012; Najafi 2013), and two were cross-over studies (Dana-
Haeri 1983; Cleland 1995). A total of 356 women aged between 13
and 45 years were randomised to these studies. One of the studies
also included 164 women with non-catamenial epilepsy; only 130
women with catamenial epilepsy were relevant to the review (Her-
zog 2012). Consequently, 192 women from the four studies were
relevant to this review.
Two studies reported on women with focal epilepsy (Dana-Haeri
1983; Herzog 2012); one study reported on focal and generalised
onset epilepsies (Najafi 2013); and one study did not report pa-
tient classification of epilepsy (Cleland 1995). Two studies includ-
ed women with either a C1 or C3 pattern of seizure exacerbation
(Dana-Haeri 1983; Najafi 2013); one study included all catamenial
patterns (Herzog 2012); and one study did not report the specif-
ic pattern of catamenial seizures (Cleland 1995). Two studies ad-
ministered progesterone during the second half of the cycle (Her-
zog 2012; Najafi 2013); one study administered norethisterone dur-
ing day 5 to 28 (Dana-Haeri 1983); and one study administered
norethisterone but did not specify when during the menstrual cycle
(Cleland 1995).
Studies comparing norethisterone and placebo
Cleland 1995 published in abstract form a single-centre UK, place-
bo-controlled, cross-over study of norethisterone (0.35 mg/day) in
15 women under double-blind conditions. The only reported inclu-
sion criteria item was a documented catamenial exacerbation of
epilepsy. Women were randomised to receive six months of either
norethisterone (0.35 mg daily) or placebo treatment followed by a
two-month wash-out period, followed by six months of the other
treatment. None of the women withdrew from the study, and all
randomised participants were included in the reported analysis.
Dana-Haeri 1983 reported on a single-centre UK, placebo-con-
trolled, cross-over study of high- and low-dose norethisterone in
9 women aged between 20 and 30 years under double-blind con-
ditions. Women were included if they demonstrated a catame-
nial pattern of seizures defined as: an increased seizure frequen-
cy or occurrence of generalised seizures before (luteal phase) or
during menstruation in at least 5 of 12 menstrual cycles. Women
were randomised to either placebo, norethisterone 1.05 mg/day, or
norethisterone 15 mg/day and observed through each treatment
for four menstrual cycles (day 5 to day 26), then switched to the oth-
er treatment arms. At the end of the 12 cycles each woman was ob-
served for 1 to 2 months without taking any hormonal treatment.
None of the women withdrew from the study, and all randomised
participants were included in the reported analysis.
Studies comparing progesterone and placebo
Herzog 2012 reported on a multicentre, placebo-controlled, par-
allel study of progesterone 600 mg/day in 294 women aged 13 to
45 years under double-blind conditions. Women were included if
they had focal onset epilepsy (as evidence by electroencephalo-
gram (EEG)) and intractable seizures (persistent seizures despite
trials of two or more antiepileptic drugs) and a seizure frequen-
cy of two or more per month in a three-month baseline period.
Women were excluded if they had a progressive neurologic or sys-
temic disorder or more than two-fold elevation in liver enzyme lev-
els. None of the women were taking major tranquillisers or contra-
ceptives during the three months prior to enrolment. Following a
three-month baseline period, women were classified into catame-
nial (n = 130) or non-catamenial stratum (n = 164). Catamenial stra-
ta included the following types of seizure pattern: C1: perimenstru-
al, C2: periovulatory, or C3: entire luteal phase. Women were ran-
domised to one of two treatment arms consisting of a placebo or
progesterone 600 mg/day taken on days 14 to 28 for three menstru-
al cycles. Thirty-three of the 130 catamenial women withdrew from
the study. The study reported outcomes for 124 catamenial women,
with six women (progesterone arm) excluded for unknown reasons
from the primary analysis.
Najafi 2013 reported on a single-centre, Iranian-based, place-
bo-controlled, parallel study of progesterone (Mejestrol) 80 mg/
day in 38 women, mean age 30.5 years, under double-blind con-
ditions. Women were included if they experienced focal or gener-
alised seizures and a catamenial pattern defined as either a two-
fold increase in seizures during: premenstrual (day −3 to day +2) or
whole of luteal phase (day 2 to day 10) together with a low proges-
terone level (< 5 mg/mL) in the mid-luteal phase for luteal exacerba-
tions of seizures. Exclusions included pregnancy, lactating, the use
of major tranquilisers and antidepressants, abnormal menses, con-
traceptive use, previous history of thromboemboli, and not willing
to consent. The description of an inadequate luteal phase is not typ-
ically defined as day 2 to day 10, although the study reports mea-
suring a mid-luteal progesterone level in the third week of the cycle
or 21st day, or both. Following a 3-month baseline period, women
were assigned randomly to either placebo or 80 mg/day of prog-
esterone (Mejestrol) taken on day 15 to day 25. Two women in the
progesterone group withdrew from the study and were excluded
from the primary analysis.
Excluded studies
See: Characteristics of excluded studies
We excluded four studies for the following reasons: one study had
a treatment period of less than 12 weeks (Feely 1982), and the re-
maining three studies were terminated early due to poor recruit-
ment (NCT00630630), a change in protocol (NCT00559169), and by
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the institutional review board (NCT00530413), with no results avail-
able.
Risk of bias in included studies
See: Figure 3; Figure 4
 
Figure 3.   Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages
across all included studies.
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Figure 4.   Risk of bias summary: review authors' judgements about each risk of bias item for each included study.
 
Allocation
Two trials reported adequate methods of randomisation and were
judged to be at low risk of bias: one trial used block randomisation
(block size six) conducted separately for women with and without
catamenial epilepsy (Herzog 2012), and one trial used random allo-
cation software to randomly divide consecutive patients into two
groups (Najafi 2013). The remaining two trials did not report meth-
ods used in random sequence generation and were judged to be
at unclear risk of bias (Dana-Haeri 1983; Cleland 1995). None of the
trials reported methods of allocation concealment and were are all
judged to be at unclear risk of bias for this item.
Blinding
All trials reported adequate methods of blinding of participants and
personnel and were judged to be at low risk of bias. All studies were
double-blind and used matched placebo tablets. We assessed the
risk of bias for blinding of outcome assessors as unclear in three
trials for which no details were reported (Dana-Haeri 1983; Cleland
1995; Najafi 2013). The fourth trial reported that the statistician,
pharmacist, and study safety monitor were all blinded to the out-
come, hence this study was judged to be at low risk of bias (Herzog
2012).
Incomplete outcome data
We assessed the risk of bias for incomplete outcome data as un-
clear in three studies (Dana-Haeri 1983; Cleland 1995; Herzog 2012),
as there were inconsistencies and limited information on the num-
ber of women used in calculating outcomes and whether an inten-
tion-to-treat method was used. We judged the fourth study to be
at high risk of bias as it excluded two participants within the prog-
esterone treatment group due to adverse events, analysing only
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those who completed the study using an evaluable-case analysis
(Najafi 2013). This form of analysis is prone to inaccurate estimates
since it unreasonably assumes that those who discontinue treat-
ment are representative (in terms of responder status) of those who
remain.
Selective reporting
The four trials reported on either seizure outcomes, adverse events,
number who withdrew, or a combination of these outcomes. None
of the studies reported on quality of life outcomes. We assessed two
trials as at low risk of reporting bias (Herzog 2012; Najafi 2013). The
other two trials did not provide sufficient information to assess se-
lective reporting bias (unclear risk of reporting bias) (Dana-Haeri
1983; Cleland 1995).
Other potential sources of bias
There was insufficient information available to assess for other
sources of bias in two trials (Dana-Haeri 1983; Cleland 1995). We
judged one trial reporting balanced baseline characteristics across
treatment groups to be at low risk of bias with no other sources of
bias detected (Najafi 2013). We assessed the fourth trial as at high
risk of other sources of bias (Herzog 2012). The trial was significant-
ly underpowered, with only 130 catamenial women recruited out of
a target sample size of 640 (to include a sample size of 192 women
within the catamenial stratum) to demonstrate a significant differ-
ence between progesterone and placebo (power = 0.80; α = 0.05).
The trial was stopped early due to futility analyses showing that the
blinded conditional power of the comparison for the primary out-
come for that stratum had dropped below 50%. The authors iden-
tified a biological problem with the original design, reporting that
failure of the trial to prove the principal hypothesis may relate to
the design, which attempted to treat all three patterns of catame-
nial epilepsy, which are likely to differ in pathophysiology with a
single treatment regimen.
E<ects of interventions
See: Summary of findings for the main comparison Norethis-
terone compared to placebo for perimenstrual seizures in catame-
nial epilepsy; Summary of findings 2 Progesterone compared to
placebo for perimenstrual seizures in catamenial epilepsy
Norethisterone versus placebo
Two included studies recruiting 24 women compared norethis-
terone to placebo (Dana-Haeri 1983; Cleland 1995). Both were
cross-over studies and provided limited numerical results for the
outcomes relevant to this review, therefore results of these stud-
ies were described narratively, and the certainty of the evidence for
all reported outcomes for this comparison was graded as very low
(Summary of findings for the main comparison).
Primary outcomes
Seizure freedom
Neither study reported on seizure freedom (Dana-Haeri 1983; Cle-
land 1995).
Responder rate
Neither study reported on responder rate (Dana-Haeri 1983; Cle-
land 1995).
Change in seizure frequency
One study reported that the number of seizures outside key
days was higher with norethisterone, whereas the exacerbation of
seizure frequency during key days was lower with norethisterone.
The authors note that "no statistically significant differences be-
tween the treatment groups was shown", but no numerical results
were presented to support this (Cleland 1995).
One study reported mean seizure frequencies per menstrual cycle
over four menstrual cycles. None of the nine participants in this
study showed a significant decrease in seizure frequency whilst tak-
ing the high and low doses of norethisterone compared with the
placebo. The authors also reported that there was no significant de-
crease in seizure frequency when tonic-clonic and complex-partial
catamenial seizures were considered separately (Dana-Haeri 1983).
Secondary outcomes
Withdrawals
No withdrawals were reported in either of the studies (Dana-Haeri
1983; Cleland 1995).
Adverse events
One study did not report on adverse events (Dana-Haeri 1983).
The other study reported limited information on adverse events
(Cleland 1995). The study reported four "mild" types of adverse
event that were considered to be related to the trial medication in
eight out of 14 randomised women: irregularities in menstrual cycle
(five women), facial rash (one woman), headaches (two women),
mild swelling of hands and feet (one woman), and bloated feel-
ing (one woman). We assume that participants could have report-
ed more than one adverse event, and that these events occurred
whilst participants were taking norethisterone, but this informa-
tion was not explicitly stated.
Quality of life outcomes
Neither study reported on quality of life outcomes (Dana-Haeri
1983; Cleland 1995).
Progesterone versus placebo
Two included studies recruiting 168 women with catamenial
epilepsy compared progesterone to placebo (Herzog 2012; Najafi
2013). One of the studies recruited women with catamenial and
women with non-catamenial epilepsy (Herzog 2012); only results
for the stratum with catamenial epilepsy are reported in this re-
view. We assessed the certainty of the evidence for this comparison
as moderate to low (Summary of findings 2).
Primary outcomes
Seizure freedom
One study did not report on seizure freedom (Najafi 2013).
Data from one study contributed to this outcome (Herzog 2012).
The difference in the proportion of women achieving seizure free-
dom of all seizure types was not statistically significant (3/79, 3.8%
progesterone versus 0/45, 0% placebo) (risk ratio (RR) 4.03, 95%
confidence interval (CI) 0.21 to 76.21, P = 0.35, low-certainty evi-
dence, Analysis 1.1). However, the CIs around the RR were very wide
due to the low number of women achieving seizure freedom, there-
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fore we cannot rule out an advantage to progesterone over place-
bo, or vice versa, or no difference between treatments.
The difference in the proportion of women achieving seizure free-
dom of the most severe seizure type was also not statistically sig-
nificant (11/79, 13.9% progesterone versus 3/45, 6.7% placebo) (RR
2.09, 95% CI 0.61 to 7.10, P = 0.18, low-certainty evidence, Analysis
1.1). Again, however, the CIs around the RR were very wide due to
the low number of women achieving seizure freedom, therefore it
is difficult to draw any conclusions.
Responder rate
One study did not report on responder rate (Najafi 2013).
Data from one study contributed to this outcome (Herzog 2012).
The difference in the proportion of responders for all seizure types
was not statistically significant (18/79, 22.8% progesterone versus
9/45, 20% placebo) (RR 1.14, 95% CI 0.56 to 2.32, P = 0.71, moder-
ate-certainty evidence, Analysis 1.2).
The difference in the proportion of responders for the most se-
vere seizure type was also not statistically significant (11/79, 13.9%
progesterone versus 3/45, 6.7% placebo) (RR 1.24, 95% CI 0.67 to
2.29, P = 0.47, moderate-certainty evidence, Analysis 1.2). The pro-
portions of responders for each seizure type considered individu-
ally (complex focal, simple focal, secondary generalised seizures)
did not differ significantly between progesterone and placebo (see
Analysis 1.2).
Change in seizure frequency
Both trials contributed to this outcome (Herzog 2012; Najafi 2013),
but due to the way the results were presented in the studies, data
could not be combined in meta-analysis. We assessed the certainty
of the evidence for this outcome as low.
One study reported the mean seizure frequency in the three months
before and the three months after the study (Najafi 2013). There
was no difference between treatment groups in terms of seizure fre-
quency in the three months before baseline (mean difference (MD)
−1.40, 95% CI −4.39 to 1.59, P = 0.36, Analysis 1.3), but there was
a statistically significant advantage for progesterone over placebo
in terms of seizure frequency in the three months after baseline
(MD −4.50, 95% CI −6.55 to −2.45, P <0.001, Analysis 1.3). The orig-
inal study also reports that a repeated-measures analysis of vari-
ance (ANOVA) was conducted to test the difference between treat-
ment groups over time; the authors concluded that the decrease in
seizure frequency from baseline in the progesterone group is signif-
icantly higher than the decrease in seizure frequency from baseline
in the placebo group (P = 0.024).
One study reported the median and interquartile range of the
per cent change in seizure frequency with progesterone treatment
compared to placebo (Herzog 2012). The results are summarised
in Table 1; the median reductions in seizure frequency were 19.9%
and 12.0% in the progesterone and placebo groups respectively,
but this difference was not statistically significant. The median re-
ductions for the most severe seizure type or each seizure type con-
sidered separately (complex focal, simple focal, secondary gener-
alised seizures) ranged from 15.4% to 38.1% in the progesterone
group and 0% to 25.7% in the placebo group; again, none of the dif-




Both trials contributed to this outcome (Herzog 2012; Najafi 2013).
A total of 26 out of 104 participants (25%) withdrew from proges-
terone: due to adverse events (n = 6), withdrew after treatment (n
= 6), change in antiepileptic drug (n = 3), inappropriate menstrual
cycle length (n = 3), compliance < 80% (n = 3), lost to follow-up (n
= 1), and other, unspecified reason (n = 4). Nine out of 64 partici-
pants (14%) withdrew from placebo: due to adverse events (n = 1),
withdrew after treatment (n = 5), change in antiepileptic drug (n =
1), and other, unspecified reason (n = 2). No treatment withdrawals
due to lack of efficacy were reported in either study.
There was no significant difference between progesterone and
placebo in the two studies in terms of treatment withdrawals for
any reason (pooled RR 1.56, 95% CI 0.81 to 3.00, P = 0.18, I2 =
0%, moderate-certainty evidence, Analysis 1.4) or treatment with-
drawals due to adverse events (pooled RR 2.91, 95% CI 0.53 to 16.17,
P = 0.22, I2 = 0%, moderate-certainty evidence, Analysis 1.4).
Adverse events
Both trials contributed to this outcome (Herzog 2012; Najafi 2013).
In Najafi 2013, two women were excluded from the study due to
progesterone side effects (severe headache, nausea and vomit-
ing). No further information on adverse events was provided in this
study.
At least one adverse event was reported in 37 out of 85 women
(43.5%) randomised to progesterone and 23 out of 45 women (51%)
randomised to placebo in Herzog 2012. There was no significant dif-
ference in the proportion of women experiencing adverse events
on progesterone versus placebo (RR 0.85, 95% CI 0.59 to 1.24, P =
0.41, moderate-certainty evidence, Analysis 1.5).
Adverse events reported in at least 5% of participants in Her-
zog 2012 (diarrhoea, dyspepsia, nausea, vomiting, fatigue, na-
sopharyngitis, dizziness, headache, and depression) are sum-
marised in Analysis 1.6. There was no significant difference in the
proportion of women experiencing any of these adverse events be-
tween progesterone and placebo (99% CIs presented to allow for
multiple statistical testing).
Nine serious adverse events (SAE) were reported during treatment
in Herzog 2012, however these events were not separated into cata-
menial epilepsy and non-catamenial epilepsy subgroups. The most
common SAE was hospitalisation for seizures (two women on prog-
esterone and three on placebo). Three additional SAEs were report-
ed on progesterone treatment, but they were considered unlike-
ly to be related to progesterone (stomach flu, thyroid carcinoma,
blurred vision). One death occurred on progesterone, which was at-
tributed to sudden unexplained death in epilepsy and considered
unlikely to be related to the progesterone treatment.
Quality of life outcomes
Neither study reported on quality of life outcomes (Herzog 2012;
Najafi 2013)
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D I S C U S S I O N
Summary of main results
All four randomised controlled trials (RCTs) included in this review
trialled hormonal treatments in women with catamenial epilepsy.
One study reported on the 50% responder rate for progesterone 600
mg/day taken on days 14 to 28 versus placebo in catamenial epilep-
sy of any pattern (Herzog 2012). There were no statistically signif-
icant differences for the proportion of responders for all seizure
types who had been randomised to progesterone versus placebo
(RR 1.14, 95% CI 0.56 to 2.32, P = 0.71). Proportions of responders for
each seizure type considered individually (complex focal, simple fo-
cal, secondary generalised seizures) did not differ significantly be-
tween progesterone and placebo. The same study (and only study
to report on the proportion seizure-free) did not detect any signifi-
cant differences between treatment groups for all seizures (RR 4.03,
95% CI 0.21 to 76.21, P = 0.35) or when seizures types were consid-
ered individually (Herzog 2012).
All studies reported on changes in mean seizure frequency (Dana-
Haeri 1983; Cleland 1995; Herzog 2012; Najafi 2013), however due
to the way that results were presented in the studies, the data
could not be combined in meta-analysis for either progesterone or
norethisterone. The norethisterone RCTs did not report any signifi-
cant change in mean seizure frequency between groups, although
the sample sizes were very small and detail on data outcomes
is very limited (Dana-Haeri 1983; Cleland 1995). For progesterone
RCTs, the studies reported conflicting results (Herzog 2012; Najafi
2013). One small RCT demonstrated a statistically significant reduc-
tion in mean seizure frequency (MD −4.50, 95% CI −6.55 to −2.45,
P < 0.001) with progesterone 80 mg/day taken on day 15 to day
25 when compared to placebo in the three months after baseline
(Najafi 2013). The other, larger RCT did not demonstrate a signif-
icant difference between progesterone 600 mg/day taken on day
14 to 28 and placebo with respect to proportional changes for all
seizures combined, most severe seizure type, or each seizure type
considered separately (complex focal, simple focal, secondary gen-
eralised seizures) (Herzog 2012).
Results for the outcome treatment withdrawal were reported in the
two progesterone RCTs but in neither of the norethisterone RCTs.
For the two progesterone RCTs (Herzog 2012; Najafi 2013), there
was no significant difference between progesterone and placebo
in terms of treatment withdrawals for any reason (pooled RR 1.56,
95% CI 0.81 to 3.00, P = 0.18, I2 = 0%) or treatment withdrawals due
to adverse events (pooled RR 2.91, 95% CI 0.53 to 16.17, P = 0.22,
I2 = 0%).
Limited information was reported for adverse events with norethis-
terone (Dana-Haeri 1983; Cleland 1995). One study reported men-
strual irregularities and headaches as the most frequently occur-
ring adverse events, although it is unclear whether these out-
comes related to patients taking norethisterone (Cleland 1995).
For progesterone, one study showed no significant difference be-
tween progesterone and placebo in the proportion of women ex-
periencing any adverse event (RR 0.85, 95% CI 0.59 to 1.24, P =
0.41) or any specific adverse event that occurred in at least 5% of
participants (diarrhoea, dyspepsia, nausea, vomiting, fatigue, na-
sopharyngitis, dizziness, headache, and depression) (Herzog 2012).
The other study reported limited information on adverse events,
although two women were excluded from the study due to severe
headache, nausea and vomiting (Najafi 2013).
None of the RCTs reported quality of life outcomes, therefore the
effect of norethisterone and progesterone on this outcome is un-
clear.
Overall completeness and applicability of evidence
This review highlights a significant deficiency within the evidence
base for clinical studies of treatments used in catamenial epilepsy.
The included RCTs provide very limited data on the effectiveness of
norethisterone and progesterone in catamenial epilepsy with reg-
ular menses. These trials had small sample sizes, short treatment
durations, and differed in their inclusion of different patterns of
catamenial seizures. According to the available data, the majority
of women included in these RCTs had focal epilepsy. Given that the
RCTs were all significantly underpowered, the outcomes lack preci-
sion and therefore a treatment effect for norethisterone and prog-
esterone cannot be ruled out.
We found no RCTs for non-hormonal treatments of catamenial
epilepsy or for women with irregular menses.
Different catamenial patterns of seizures were treated in the same
way despite proposed differences in pathophysiological mecha-
nisms. Methodological differences, small sample sizes, differences
in definitions of catamenial strata, and incomplete baseline and de-
mographic details make applicability of this evidence very limited.
A post hoc analysis was reported by Herzog 2012 and ascertained
that women with a three-fold increase in seizure frequency (C1 pat-
tern, 21.4% of the women recruited into the trial) had a statistically
significant response to progesterone treatment when compared to
the combined placebo group (responder rate 37.8% versus 11.1%,
P = 0.037). However, high-quality clinical trials are required to ex-
amine this outcome further.
Certainty of the evidence
The included RCTs used appropriate methods of participant and
personnel blinding, but other quality domains were for most stud-
ies judged to be at unclear risk of bias. None of the RCTs reported
an explicit analysis by intention-to-treat, and one RCT excluded two
women in the final analyses due to adverse events. Three of four
RCTs recruited very small sample sizes, and the largest RCT was ter-
minated early due to under-recruitment.
We judged the evidence from the included norethisterone RCTs to
be of very low certainty due to serious imprecision and risk of bias:
the two studies used a cross-over design, had very small sample
sizes, and reported limited information regarding study design and
numerical results. We judged the evidence from the included prog-
esterone RCTs to be of low to moderate certainty due to risk of bias:
unclear methodological information regarding allocation conceal-
ment and attrition; imprecision around treatment effects due to
small numbers of events; inconsistencies between studies in re-
ported methodologies, results, and conclusions.
Potential biases in the review process
There is a possible risk of publication bias in this review given that
there are a number of studies awaiting classification. It is also pos-
sible that despite the exhaustive searches carried out in this review
other sources of data have not been identified.
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Agreements and disagreements with other studies or
reviews
We are not aware of any other systematic reviews on treatments for
perimenstrual seizures in catamenial epilepsy.
A U T H O R S '   C O N C L U S I O N S
Implications for practice
Overall, this review provides very low-certainty evidence of com-
parable effectiveness of norethisterone, and moderate- to low-
certainty evidence of comparable effectiveness of progesterone,
both versus placebo for catamenial epilepsy. The review pro-
vides moderate-certainty evidence for comparable tolerability of
progesterone compared to placebo for adverse events (diarrhoea,
dyspepsia, nausea, vomiting, fatigue, nasopharyngitis, dizziness,
headache, and depression) and retention. The review provides
no information on the comparative tolerability of norethisterone
when compared to placebo.
The review sadly highlights an overall deficiency in the literature
base on the effectiveness of a wide range of other hormonal and
non-hormonal interventions currently being used in practice, par-
ticularly for those women who do not have regular menses.
Implications for research
Despite the clinical importance of seizures in catamenial epilepsy
and the high frequency of this pattern experienced in women, the
literature base for high-quality randomised controlled trials is lack-
ing. Current trials largely in focal epilepsy attempted to treat var-
ious patterns of catamenial epilepsy using a single treatment reg-
imen, which may represent a design fault in view of the likely dif-
ferences in pathophysiology. For example, progesterone may have
greater efficacy where progesterone withdrawal is the key patho-
physiological change (C1 or C3 pattern), but may have limited or no
effect of preovulatory seizures, where the proposed mechanism re-
lates to oestrogen surge.
Any further research studies into this area must address the var-
ious pathophysiological mechanisms within the design concept.
This may necessitate large sample sizes and multicentre collabora-
tion. A future randomised controlled trial examining treatments for
those with very high seizure exacerbations as part of a particular
catamenial pattern may also be useful.
Areas of trial research might be to consider progesterone earlier in
the cycle for C2 pattern of seizures, or to use alternate strategies, for
example depot medroxyprogesterone acetate or gonadotropin-re-
leasing hormone (GnRH) analogues for this pattern (Bauer 1992;
Haider 1991). Similarly, trials are needed to examine the effects of
hormonal and non-hormonal strategies in individuals with prima-
ry generalised forms of epilepsy (e.g. juvenile myoclonic epilepsy)
where onset of seizures occur in puberty.
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Characteristics of included studies [ordered by study ID]
 
Methods Double-blind randomised controlled trial, cross-over design
Participants 15 female participants with documented catamenial exacerbation of epilepsy.
Age, epilepsy duration, and seizure frequency at baseline of participants not reported.
Interventions 6 months of either norethisterone (0.35 mg daily) or placebo treatment, followed by 2-month wash-out
followed by 6 months of the other treatment; usual medication was continued
Outcomes Side effects
Mean menstrual cycle length
Number of seizures outside of 'key days'
Exacerbation of seizure frequency outside of 'key days'
Funding Not stated
Cleland 1995 
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Conflict of Interest Not stated
Notes Study reported as an abstract only. Very limited information regarding design reported.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Described as randomised, but no further information provided
Allocation concealment
(selection bias)





Low risk Study described as double-blind and a placebo was used.
Blinding of outcome as-
sessment (detection bias) 
All outcomes




Unclear risk Inconsistent information throughout the abstract: 5 women studied, 8 out of
14 women had adverse events, but no women withdrew from the study. Un-
clear how many women were studied
Selective reporting (re-
porting bias)
Unclear risk Insufficient information reported in the abstract to make a judgement




Methods Double-blind randomised controlled trial, cross-over design
Participants 9 female participants aged 20 to 30 years with catamenial exacerbation occurring in at least 5 of 12
menstrual cycles were included.
Participants were either residents at the Chalfont Centre for Epilepsy or outpatients at the National
Hospital, London.
Epilepsy duration and seizure frequency at baseline not stated.
Interventions 3 treatment periods, each of 4 menstrual cycles, followed by observation for 1 to 2 months:
• Low-dose norethisterone (5 mg 3 times daily as Primolut-Na tablets)
• High-dose norethisterone 350 μg 3 times daily as Micronor tablets
• Size- and colour-matched placebo pills
8 women had been taking either single or combination antiepileptic drug therapy for a long time. 1
woman had discontinued taking carbamazepine and was not taking any antiepileptic drugs.
Outcomes Seizure frequency during 4 menstrual cycles with each treatment
Dana-Haeri 1983 
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Results presented separately for individuals with tonic-clonic seizures and individuals with complex
partial and simple partial seizures.
Funding Not stated
Conflict of Interest Not stated
Notes Unclear if there was a wash-out period between treatment periods (but very limited information pro-
vided on study design, therefore study included despite clear information about wash-out period)
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Described as randomised, but no further information provided
Allocation concealment
(selection bias)





Low risk Study described as double-blind, size- and colour-matched placebos used.
Blinding of outcome as-
sessment (detection bias) 
All outcomes








Unclear risk No protocol available, outcomes and statistical methods reported in brief.
Limited data reported relating to seizures, and adverse events not reported;
unclear if any further information was measured but not recorded.
Other bias Unclear risk Very limited information provided on study design and participant character-
istics. Unclear if there was a wash-out period between treatment periods. Un-




Methods Double-blind, phase III, parallel-group, randomised (2:1 ratio) controlled trial conducted at 15 hospitals
in the USA
Participants Female participants, aged 13 to 45 years old, with intractable seizures despite trials of > 2 antiepileptic
drugs at therapeutic levels and monthly menses with intervals of 23 to 35 days. 294 participants with
catamenial or non-catamenial epilepsy were recruited (randomisation stratified by catamenial or non-
catamenial epilepsy); only 130 participants with catamenial epilepsy are relevant to the review.
Mean age +/−SD (range): progesterone: 31.4 +/− 8.68 (11 to 45); placebo: 32.31 +/− 8.50 (14 to 45)
Duration of epilepsy (years): mean +/− SD (range): progesterone: 18.11 +/− 10.24 (1 to 39); placebo:
18.60 +/− 10.76 (1 to 37)
Herzog 2012 
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Interventions Treatment consisted of identical progesterone 200 mg or placebo lozenges, taken 3 times daily on days
14 to 28 of treatment cycles.
130 randomised (124 analysed): progesterone: 85 randomised/79 analysed; placebo: 45 randomised/45
analysed
3 baseline menstrual cycles; 3 treatment menstrual cycles were analysed
Outcomes Primary outcome:
• Per cent of responders for all seizures combined during treatment as compared to baseline
Secondary outcomes:
• Per cent of women who showed 50% reduction in average daily seizure frequency for the most se-
vere seizure type and individual seizure types (secondary generalised motor seizures, complex partial
seizures, simple partial seizures)
• Per cent of women who became seizure-free
• Change in average daily seizure frequency for all seizures combined, the most severe seizure type, and
individual seizure types
Funding This research was supported by a National Institutes of Health (NIH) research grant: NIH NINDS R01
39466.
Conflict of Interest Full disclosures available in the journal article and on the online version of the journal article.
Notes Body mass index, seizure type, age at onset of epilepsy, epilepsy focus, laterality and basis of localisa-
tion at baseline were also reported. No significant differences between groups
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Blocked randomisation (block size of 6), conducted separately for women with
and without catamenial epilepsy was conducted by an unblinded statistician.
Allocation concealment
(selection bias)





Low risk Study was double-blinded, and placebo lozenges used.
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk “Unblinded throughout the study (2000-2010) were the unblinded statistician,
research pharmacist and study safety monitor.” ClinicalTrials.gov entry also




Unclear risk Attrition rates and reasons reported; the paper states that an intention-to-
treat approach was used, but it is unclear why only 79 women (out of 85 ran-
domised to progesterone) are included in the responder analyses.
Selective reporting (re-
porting bias)
Low risk All outcomes specified in the methods section and on ClinicalTrials.gov are
well reported in the results of the paper. All expected outcomes reported.
Other bias High risk Underpowered - expected recruitment compared to actual recruitment.
The trial was stopped early due to futility analyses showing that the blinded
conditional power of the comparison for the primary outcome for that stratum
Herzog 2012  (Continued)
Treatments for seizures in catamenial (menstrual-related) epilepsy (Review)









Cochrane Database of Systematic Reviews
dropped below 50%. The trial is underpowered for the original hypothesis, but
was stopped for the benefit of the participants, and the authors have identified
a biological problem with the original design.
“Failure of the trial to prove the principal hypothesis may relate to the design
that attempted to treat 3 patterns of catamenial epilepsy which likely differ in




Methods Double-blind, parallel-group randomised controlled trial conducted at the Isfahan University of Med-
ical Sciences between June 2011 and March 2012
Participants Female participants with either complex partial seizure, secondary generalised seizure, or primary gen-
eralised seizure and received full‑dose antiepileptic drugs. Seizure patterns had to be in the cata-
menial form, and seizure had to become exacerbated during the premenstrual period (between the
25th day of the previous cycle and the second day of the next cycle) or the whole period of the luteal
phase of the cycle (2nd to 10th days of the cycle).
Mean age 30.5 ± 8.5 years (overall)
Progesterone group (n = 17): mean (SD) 29.2 (8.7); median (IQR) 27 (21.5 to 35)
Placebo group (n = 19): mean (SD) 32.1 (8.3); median (IQR) 33 (26 to 36)
Epilepsy duration (years, overall): mean 16.3 ± 9.3 years
Progesterone group (n = 17): mean (SD) 15.1 (9.7); median (IQR) 13 (9 to 18)
Placebo group (n = 19): mean (SD) 17.5 (8.8); median (IQR) 15 (13 to 20)
Seizures in the 3 months before the study (overall): mean 7.8 ± 7.2 years
Progesterone group (n = 17): mean (SD) 6.2 (3.4); median (IQR) 5 (4 to 8)
Placebo group (n = 19): mean (SD) 7.6 (5.6); median (IQR) 8 (3 to15)
Interventions Two 40 mg progesterone tablets daily (twice a day) in the 2nd half of the cycle from 15th to 25th day
Two placebo tablets daily in the same manner
38 randomised (36 analysed): progesterone: 19 randomised/17 analysed; placebo: 19 randomised/19
analysed
All participants took concomitant antiepileptic drugs.
Analysis after 3 months of follow-up (monthly visits and number of seizures recorded).
Outcomes Comparison of number of seizures during 3 months before and after the study
Funding No funding provided for the study.
Conflict of Interest None declared.
Notes No statistically significant difference in characteristics between groups
Risk of bias
Bias Authors' judgement Support for judgement
Najafi 2013 
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Random sequence genera-
tion (selection bias)
Low risk Consecutive patients meeting the inclusion criteria were randomly divided in-
to 2 groups using Random Allocation Software (Saghaei 2004).
Allocation concealment
(selection bias)





Low risk Double-blind, placebo tablets were manufactured that were formally the
same.
Blinding of outcome as-
sessment (detection bias) 
All outcomes




High risk 2 participants in the progesterone group were excluded from the study due to
adverse events. Only those who completed the study were analysed.




Low risk Outcome reported in the registry entry (seizure frequency at 3 months) report-
ed in the publication. Adverse events also reported.






Characteristics of excluded studies [ordered by study ID]
 
Study Reason for exclusion
Feely 1982 Treatment period was less than 12 weeks.
NCT00530413 Study terminated by Institutional Review Board, no results available.
NCT00559169 Study terminated due to a change in protocol, no results available.
NCT00630630 Study terminated prematurely after recruiting only 3 participants, primary and secondary out-
comes not analysed.
 
Characteristics of studies awaiting assessment [ordered by study ID]
 
Methods Phase II, randomised, double-blind, cross-over trial
Participants Female participants between the ages of 21 and 45 years with a positive diagnosis of catamenial
epilepsy
Interventions Keishibukuryogan versus placebo (added to usual antiepileptic drug treatment) for 12 weeks
NCT01299870 
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Follow-up: up to 36 weeks
Outcomes Safety (up to 36 weeks)
Change in seizure frequency (with a focus on an increase in seizure frequency, up to 36 weeks)
Change in progesterone levels (up to 36 weeks)
Notes Results "submitted" to ClinicalTrials.gov, but not published online or within any journal article




Methods Phase II, 18-week, double-blind, placebo-controlled, randomised clinical trial of ganaxolone ad-
ministered as add-on therapy in adults with uncontrolled focal onset seizures
Participants Men or women ages 18 to 69 years inclusive were eligible if they had a diagnosis of epilepsy with fo-
cal onset seizures with or without secondarily generalised seizures.
100 out of 147 recruited participants were female, and "the female predominance was likely due to
the perceived benefit for women who have catamenial epilepsy based on the ganaxolone’s mecha-
nism of action".
Interventions Ganaxolone (titrated up to 1500 mg/day) or placebo was added to existing antiepileptic drug ther-
apy of up to 3 antiepileptic drugs, which were maintained at a stable dose for at least 30 days prior
to enrolment.
Outcomes Primary outcome:
Change in mean weekly seizure frequency for all seizure types including complex focal onset
seizures, simple focal onset seizures with motor manifestations, and secondarily generalised
seizures (but excluding non-motor simple partial seizures) during the titration plus maintenance
periods (weeks 1 to 10).
Secondary outcomes:
1. Change in mean weekly seizure frequency during the maintenance period.
2. Change and per cent change from baseline of mean weekly seizure frequency during the mainte-
nance period and titration plus maintenance period.
3. Weekly seizure frequency for each week after dosing (titration plus maintenance period).
4. Mean weekly seizure frequency and change and per cent change from baseline during the titra-
tion plus maintenance period for each seizure subtype (complex partial seizure, generalised ton-
ic–clonic seizure, and simple partial seizure-motor).
5. Responder rate (≥ 50% reduction from baseline in mean weekly seizure frequency during the titra-
tion plus maintenance period from baseline).
6. Number of seizure-free days during the titration, maintenance, and titration plus maintenance
periods.
7. Number of seizure-free participants and seizure-free rate during the titration, maintenance, and
titration plus maintenance periods.
Exploratory endpoints: the Seizure Severity Questionnaire and Quality of Life in Epilepsy-31 Inven-
tory (QOLIE-31)
Notes Results were not presented separately for participants with catamenial epilepsy. We have contact-
ed the original authors to request results for the subgroup of participants with catamenial epilepsy.
Sperling 2017 
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D A T A   A N D   A N A L Y S E S
 
Comparison 1.   Progesterone versus placebo





Statistical method Effect size
1 Seizure freedom 1   Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
1.1 All seizures 1 124 Risk Ratio (M-H, Fixed, 95% CI) 4.03 [0.21, 76.21]
1.2 Most severe seizure type 1 124 Risk Ratio (M-H, Fixed, 95% CI) 2.09 [0.61, 7.10]
2 Responder rate (50% reduction in
seizure frequency)
1   Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
2.1 All seizures 1 124 Risk Ratio (M-H, Fixed, 95% CI) 1.14 [0.56, 2.32]
2.2 Most severe seizure type 1 124 Risk Ratio (M-H, Fixed, 95% CI) 1.24 [0.67, 2.29]
2.3 Secondarily generalised motor
seizures
1 50 Risk Ratio (M-H, Fixed, 95% CI) 1.34 [0.57, 3.13]
2.4 Complex partial seizures 1 119 Risk Ratio (M-H, Fixed, 95% CI) 1.27 [0.60, 2.68]
2.5 Simple partial seizures 1 51 Risk Ratio (M-H, Fixed, 95% CI) 1.0 [0.50, 2.01]
3 Seizure frequency 1   Mean Difference (IV, Fixed, 95%
CI)
Subtotals only
3.1 In the 3 months before the study 1 36 Mean Difference (IV, Fixed, 95%
CI)
-1.40 [-4.39, 1.59]
3.2 In the 3 months after the study 1 36 Mean Difference (IV, Fixed, 95%
CI)
-4.5 [-6.55, -2.45]
4 Number of withdrawals from the study 2   Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
4.1 Withdrawals for any reason 2 168 Risk Ratio (M-H, Fixed, 95% CI) 1.56 [0.81, 3.00]
4.2 Withdrawals due to adverse events 2 168 Risk Ratio (M-H, Fixed, 95% CI) 2.91 [0.53, 16.17]
5 Any adverse events reported 1   Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
6 Adverse events reported in > 5% of par-
ticipants
1   Risk Ratio (M-H, Fixed, 99% CI) Subtotals only
6.1 Diarrhoea 1 130 Risk Ratio (M-H, Fixed, 99% CI) 0.53 [0.09, 3.07]
6.2 Dyspepsia 1 130 Risk Ratio (M-H, Fixed, 99% CI) 0.53 [0.04, 6.66]
6.3 Nausea 1 130 Risk Ratio (M-H, Fixed, 99% CI) 0.08 [0.00, 3.65]
6.4 Vomiting 1 130 Risk Ratio (M-H, Fixed, 99% CI) 0.53 [0.04, 6.66]
6.5 Fatigue 1 130 Risk Ratio (M-H, Fixed, 99% CI) 1.48 [0.42, 5.20]
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Statistical method Effect size
6.6 Nasopharyngitis 1 130 Risk Ratio (M-H, Fixed, 99% CI) 0.18 [0.00, 11.65]
6.7 Dizziness 1 130 Risk Ratio (M-H, Fixed, 99% CI) 0.26 [0.05, 1.54]
6.8 Headache 1 130 Risk Ratio (M-H, Fixed, 99% CI) 0.79 [0.08, 7.94]
6.9 Depression 1 130 Risk Ratio (M-H, Fixed, 99% CI) 2.12 [0.12, 36.26]
 
 
Analysis 1.1.   Comparison 1 Progesterone versus placebo, Outcome 1 Seizure freedom.
Study or subgroup Progesterone Placebo Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
1.1.1 All seizures  
Herzog 2012 3/79 0/45 100% 4.03[0.21,76.21]
Subtotal (95% CI) 79 45 100% 4.03[0.21,76.21]
Total events: 3 (Progesterone), 0 (Placebo)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.93(P=0.35)  
   
1.1.2 Most severe seizure type  
Herzog 2012 11/79 3/45 100% 2.09[0.61,7.1]
Subtotal (95% CI) 79 45 100% 2.09[0.61,7.1]
Total events: 11 (Progesterone), 3 (Placebo)  
Heterogeneity: Not applicable  
Test for overall effect: Z=1.18(P=0.24)  
Favours Placebo 1000.01 100.1 1 Favours Progesterone
 
 
Analysis 1.2.   Comparison 1 Progesterone versus placebo,
Outcome 2 Responder rate (50% reduction in seizure frequency).
Study or subgroup Progesterone Placebo Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
1.2.1 All seizures  
Herzog 2012 18/79 9/45 100% 1.14[0.56,2.32]
Subtotal (95% CI) 79 45 100% 1.14[0.56,2.32]
Total events: 18 (Progesterone), 9 (Placebo)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.36(P=0.72)  
   
1.2.2 Most severe seizure type  
Herzog 2012 24/79 11/45 100% 1.24[0.67,2.29]
Subtotal (95% CI) 79 45 100% 1.24[0.67,2.29]
Total events: 24 (Progesterone), 11 (Placebo)  
Heterogeneity: Tau2=0; Chi2=0, df=0(P<0.0001); I2=100%  
Test for overall effect: Z=0.7(P=0.49)  
Favours Placebo 1000.01 100.1 1 Favours Progesterone
Treatments for seizures in catamenial (menstrual-related) epilepsy (Review)









Cochrane Database of Systematic Reviews
Study or subgroup Progesterone Placebo Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
   
1.2.3 Secondarily generalised motor seizures  
Herzog 2012 13/33 5/17 100% 1.34[0.57,3.13]
Subtotal (95% CI) 33 17 100% 1.34[0.57,3.13]
Total events: 13 (Progesterone), 5 (Placebo)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.67(P=0.5)  
   
1.2.4 Complex partial seizures  
Herzog 2012 18/76 8/43 100% 1.27[0.6,2.68]
Subtotal (95% CI) 76 43 100% 1.27[0.6,2.68]
Total events: 18 (Progesterone), 8 (Placebo)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.64(P=0.52)  
   
1.2.5 Simple partial seizures  
Herzog 2012 14/34 7/17 100% 1[0.5,2.01]
Subtotal (95% CI) 34 17 100% 1[0.5,2.01]
Total events: 14 (Progesterone), 7 (Placebo)  
Heterogeneity: Not applicable  
Test for overall effect: Not applicable  
Favours Placebo 1000.01 100.1 1 Favours Progesterone
 
 
Analysis 1.3.   Comparison 1 Progesterone versus placebo, Outcome 3 Seizure frequency.
Study or subgroup Progesterone Placebo Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Fixed, 95% CI   Fixed, 95% CI
1.3.1 In the 3 months before the study  
Najafi 2013 17 6.2 (3.4) 19 7.6 (5.6) 100% -1.4[-4.39,1.59]
Subtotal *** 17   19   100% -1.4[-4.39,1.59]
Heterogeneity: Not applicable  
Test for overall effect: Z=0.92(P=0.36)  
   
1.3.2 In the 3 months after the study  
Najafi 2013 17 1.2 (1.1) 19 5.7 (4.4) 100% -4.5[-6.55,-2.45]
Subtotal *** 17   19   100% -4.5[-6.55,-2.45]
Heterogeneity: Not applicable  
Test for overall effect: Z=4.31(P<0.0001)  
Favours Progesterone 105-10 -5 0 Favours Placebo
 
 
Analysis 1.4.   Comparison 1 Progesterone versus placebo, Outcome 4 Number of withdrawals from the study.
Study or subgroup Progesterone Placebo Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
1.4.1 Withdrawals for any reason  
Herzog 2012 24/85 9/45 95.92% 1.41[0.72,2.77]
Najafi 2013 2/19 0/19 4.08% 5[0.26,97.7]
Favours Progesterone 1000.01 100.1 1 Favours Placebo
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Study or subgroup Progesterone Placebo Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
Subtotal (95% CI) 104 64 100% 1.56[0.81,3]
Total events: 26 (Progesterone), 9 (Placebo)  
Heterogeneity: Tau2=0; Chi2=0.67, df=1(P=0.41); I2=0%  
Test for overall effect: Z=1.33(P=0.18)  
   
1.4.2 Withdrawals due to adverse events  
Herzog 2012 4/85 1/45 72.34% 2.12[0.24,18.39]
Najafi 2013 2/19 0/19 27.66% 5[0.26,97.7]
Subtotal (95% CI) 104 64 100% 2.91[0.53,16.17]
Total events: 6 (Progesterone), 1 (Placebo)  
Heterogeneity: Tau2=0; Chi2=0.21, df=1(P=0.65); I2=0%  
Test for overall effect: Z=1.22(P=0.22)  
Favours Progesterone 1000.01 100.1 1 Favours Placebo
 
 
Analysis 1.5.   Comparison 1 Progesterone versus placebo, Outcome 5 Any adverse events reported.
Study or subgroup Progesterone Placebo Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
Herzog 2012 37/85 23/45 0% 0.85[0.59,1.24]
Favours Progesterone 1000.01 100.1 1 Favours Placebo
 
 
Analysis 1.6.   Comparison 1 Progesterone versus placebo,
Outcome 6 Adverse events reported in > 5% of participants.
Study or subgroup Progesterone Placebo Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 99% CI   M-H, Fixed, 99% CI
1.6.1 Diarrhoea  
Herzog 2012 4/85 4/45 100% 0.53[0.09,3.07]
Subtotal (99% CI) 85 45 100% 0.53[0.09,3.07]
Total events: 4 (Progesterone), 4 (Placebo)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.93(P=0.35)  
   
1.6.2 Dyspepsia  
Herzog 2012 2/85 2/45 100% 0.53[0.04,6.66]
Subtotal (99% CI) 85 45 100% 0.53[0.04,6.66]
Total events: 2 (Progesterone), 2 (Placebo)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.65(P=0.52)  
   
1.6.3 Nausea  
Herzog 2012 0/85 3/45 100% 0.08[0,3.65]
Subtotal (99% CI) 85 45 100% 0.08[0,3.65]
Total events: 0 (Progesterone), 3 (Placebo)  
Heterogeneity: Not applicable  
Test for overall effect: Z=1.71(P=0.09)  
   
Favours Progesterone 1000.01 100.1 1 Favours Placebo
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Study or subgroup Progesterone Placebo Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 99% CI   M-H, Fixed, 99% CI
1.6.4 Vomiting  
Herzog 2012 2/85 2/45 100% 0.53[0.04,6.66]
Subtotal (99% CI) 85 45 100% 0.53[0.04,6.66]
Total events: 2 (Progesterone), 2 (Placebo)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.65(P=0.52)  
   
1.6.5 Fatigue  
Herzog 2012 14/85 5/45 100% 1.48[0.42,5.2]
Subtotal (99% CI) 85 45 100% 1.48[0.42,5.2]
Total events: 14 (Progesterone), 5 (Placebo)  
Heterogeneity: Tau2=0; Chi2=0, df=0(P<0.0001); I2=100%  
Test for overall effect: Z=0.81(P=0.42)  
   
1.6.6 Nasopharyngitis  
Herzog 2012 0/85 1/45 100% 0.18[0,11.65]
Subtotal (99% CI) 85 45 100% 0.18[0,11.65]
Total events: 0 (Progesterone), 1 (Placebo)  
Heterogeneity: Not applicable  
Test for overall effect: Z=1.06(P=0.29)  
   
1.6.7 Dizziness  
Herzog 2012 3/85 6/45 100% 0.26[0.05,1.54]
Subtotal (99% CI) 85 45 100% 0.26[0.05,1.54]
Total events: 3 (Progesterone), 6 (Placebo)  
Heterogeneity: Not applicable  
Test for overall effect: Z=1.95(P=0.05)  
   
1.6.8 Headache  
Herzog 2012 3/85 2/45 100% 0.79[0.08,7.94]
Subtotal (99% CI) 85 45 100% 0.79[0.08,7.94]
Total events: 3 (Progesterone), 2 (Placebo)  
Heterogeneity: Tau2=0; Chi2=0, df=0(P<0.0001); I2=100%  
Test for overall effect: Z=0.26(P=0.8)  
   
1.6.9 Depression  
Herzog 2012 4/85 1/45 100% 2.12[0.12,36.26]
Subtotal (99% CI) 85 45 100% 2.12[0.12,36.26]
Total events: 4 (Progesterone), 1 (Placebo)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.68(P=0.5)  
Favours Progesterone 1000.01 100.1 1 Favours Placebo
 
 
A D D I T I O N A L   T A B L E S
 
Progesterone PlaceboSeizure type
n Median (IQR) (%) n Median (IQR) (%)
P value
Table 1.   Percentage change in seizure frequency in Herzog 2012  (Continued)
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All seizures 79 −19.9 (−49.4 to 7.4) 45 −12 (−43.0 to 8.5) 0.393
Most severe
seizure type




33 −38.1 (−95.1 to 15.3) 17 −23.7 (−79.4 to 11.9) 0.797
Complex partial
seizures
76 −15.4 (−46.2 to 0.0) 43 0 (−45.7 to 21.3) 0.147
Simple partial
seizures
34 −25.2 (−84.9 to 26.0) 17 −25.7 (−93.5 to 3.16) 0.527




A P P E N D I C E S
Appendix 1. CRS Web search strategy
1 (catamenial NEAR4 epilep*) OR (catamenial NEAR4 seizure*) OR (perimenstrual NEAR4 epilep*) OR (perimenstrual NEAR4 seizure*) AND
CENTRAL:TARGET
2 (menstrua* NEAR4 epilep*) OR (menstrua* NEAR4 seizure*) AND CENTRAL:TARGET
3 (#1 OR #2) AND CENTRAL:TARGET
Appendix 2. MEDLINE (Ovid) search strategy
This strategy is based on the Cochrane Highly Sensitive Search Strategy for identifying randomized trials (Lefebvre 2011).
1. (catamenial adj4 epilep$).tw.
2. (catamenial adj4 seizure$).tw.
3. (perimenstrual adj4 seizure$).tw.
4. (perimenstrual adj4 epilep$).tw.
5. (menstrua$ adj4 epilep$).tw.
6. (menstrua$ adj4 seizure$).tw.
7. 1 or 2 or 3 or 4 or 5 or 6
8. (randomized controlled trial or controlled clinical trial or pragmatic clinical trial).pt. or (randomi?ed or placebo or randomly).ab.
9. clinical trials as topic.sh.
10. trial.ti.
11. 8 or 9 or 10
12. exp animals/ not humans.sh.
13. 11 not 12
14. 7 and 13
15. remove duplicates from 14
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Appendix 3. ClinicalTrials.gov search strategy
catamenial OR perimenstrual | Epilepsy
Appendix 4. WHO ICTRP search strategy
catamenial epilepsy OR perimenstrual epilepsy
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